stoxline Quote Chart Rank Option Currency Glossary
argenx SE (ARGX)
411.2  0.85 (0.21%)    02-27 16:00
Open: 406.25
High: 412.505
Volume: 173,937
Pre. Close: 410.35
Low: 406.25
Market Cap: 24,341(M)
Technical analysis
2024-02-27 3:43:52 PM
Short term     
Mid term     
Targets 6-month :  482.49 1-year :  563.55
Resists First :  413.09 Second :  482.49
Pivot price 397.9
Supports First :  380.07 Second :  359.66
MAs MA(5) :  407.25 MA(20) :  394.9
MA(100) :  435.37 MA(250) :  431.57
MACD MACD :  4.3 Signal :  1.4
%K %D K(14,3) :  91.3 D(3) :  88.7
RSI RSI(14): 60.8
52-week High :  550.76 Low :  327.72
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ARGX ] has closed below upper band by 8.6%. Bollinger Bands are 51.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 412.82 - 414.04 414.04 - 415.4
Low: 403.41 - 404.92 404.92 - 406.61
Close: 407.7 - 409.97 409.97 - 412.51
Company Description

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Headline News

Tue, 27 Feb 2024
Envestnet Asset Management Inc. Buys 25940 Shares of argenx SE (NASDAQ:ARGX) - AmericanBankingNEWS

Mon, 26 Feb 2024
argenx to Present at Upcoming Investor Conferences - Yahoo Finance

Sun, 25 Feb 2024
Monashee Investment Management LLC Reduces Stock Position in argenx SE (NASDAQ:ARGX) - MarketBeat

Sat, 24 Feb 2024
argenx SE (NASDAQ:ARGX) Shares Sold by Deutsche Bank AG - MarketBeat

Fri, 23 Feb 2024
ARGX Stock Quote Price and Forecast - CNN

Thu, 22 Feb 2024
argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 59 (M)
Shares Float 55 (M)
Held by Insiders 0 (%)
Held by Institutions 56.8 (%)
Shares Short 1,370 (K)
Shares Short P.Month 1,330 (K)
Stock Financials
EPS -4.1
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 51.08
Profit Margin -22.8 %
Operating Margin -23.5 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 132 %
Gross Profit (p.s.) 0
Sales Per Share 17.4
EBITDA (p.s.) -3.84
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -100.12
PEG Ratio 0.2
Price to Book value 8.03
Price to Sales 23.58
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android